J Gastric Cancer.  2016 Sep;16(3):191-194. 10.5230/jgc.2016.16.3.191.

Hypercalcemia as Initial Presentation of Metastatic Adenocarcinoma of Gastric Origin: A Case Report and Review of the Literature

• Kumar M
• Kumar A
• Kumar V
• Kaur S
• Maroules M

• KMID: 2372563
• DOI: http://doi.org/10.5230/jgc.2016.16.3.191

Abstract

Hypercalcemia of malignancy due to metastatic gastric adenocarcinoma is extremely rare; in fact, to the best of our knowledge, only three case reports of hypercalcemia associated with metastatic gastric adenocarcinoma have been published in the literature to date. Herein, we report a rare case involving a 61-year-old African-American female who had hypercalcemia at initial presentation and who was later diagnosed with poorly differentiated gastric adenocarcinoma with extensive liver metastases, without bone involvement. She was found to have elevated parathyroid hormone-related peptide and normal parathyroid hormone levels. Despite aggressive treatment, she died within a few months of diagnosis.

Keyword

Humoral hypercalcemia of malignancy; Parathyroid hormone-related peptide; Metastatic gastric adenocarcinoma; Neoplosm metastasis

MeSH Terms

Adenocarcinoma*
Diagnosis
Female
Humans
Hypercalcemia*
Liver
Middle Aged
Neoplasm Metastasis
Parathyroid Hormone
Parathyroid Hormone-Related Protein
Parathyroid Hormone
Parathyroid Hormone-Related Protein

Figure

• 

  Fig. 1 CT Abdomen showing multiple hypodense lesions in liver.

• 

  Fig. 2 Poorly differentiated carcinoma of histopathology of liver tissue (HPF, ×50).

• 

  Fig. 3 Large ulcerated mass in distal part of stomach on esophagogastroduodenoscopy.

• 

  Fig. 4 Poorly differentiated primary gastric adenocarcinoma on histopathology of gastric mass (HPF, ×50).

• 

  Fig. 5 Positive CDX2 on immunohistochemistry of gastric mass (HPF, ×20).

Reference

1. Vassilopoulou-Sellin R, Newman BM, Taylor SH, Guinee VF. Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer. 1993; 71:1309–1312.

2. Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT. Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med. 1990; 112:499–504.

3. Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005; 352:373–379.

4. Burtis WJ, Brady TG, Orloff JJ, Ersbak JB, Warrell RP Jr, Olson BR, et al. Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med. 1990; 322:1106–1112.

5. Monno S, Nagata A, Furuta S. Hypercalcemia of cancer in the digestive tract. J Clin Gastroenterol. 1987; 9:78–82.

6. Nakayama K, Fukumoto S, Takeda S, Takeuchi Y, Ishikawa T, Miura M, et al. Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. J Clin Endocrinol Metab. 1996; 81:607–611.

7. Horwitz MJ, Tedesco MB, Sereika SM, Hollis BW, Garcia-Ocaña A, Stewart AF. Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers. J Clin Endocrinol Metab. 2003; 88:1603–1609.

8. Nakajima K, Tamai M, Okaniwa S, Nakamura Y, Kobayashi M, Niwa T, et al. Humoral hypercalcemia associated with gastric carcinoma secreting parathyroid hormone: a case report and review of the literature. Endocr J. 2013; 60:557–562.

9. Truong NU, deB Edwardes MD, Papavasiliou V, Goltzman D, Kremer R. Parathyroid hormone-related peptide and survival of patients with cancer and hypercalcemia. Am J Med. 2003; 115:115–121.

10. Engelich G, Swan N, Hartshorn KL. Raised plasma parathyroid hormone related peptide in gastric adenocarcinoma. J Clin Pathol. 2000; 53:643–644.

11. Alipov GK, Ito M, Nakashima M, Ikeda Y, Nakayama T, Ohtsuru A, et al. Expression of parathyroid hormone-related peptide (PTHrP) in gastric tumours. J Pathol. 1997; 182:174–179.

12. Deans C, Wigmore S, Paterson-Brown S, Black J, Ross J, Fearon KC. Serum parathyroid hormone-related peptide is associated with systemic inflammation and adverse prognosis in gastroesophageal carcinoma. Cancer. 2005; 103:1810–1818.

13. Abdeen O, Pandol SJ, Burton DW, Deftos LJ. Parathyroid hormone-related protein expression in human gastric adenocarcinomas not associated with hypercalcemia. Am J Gastroenterol. 1995; 90:1864–1867.